利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

35 条记录 (耗时 0.02 秒)

    METHOD AND APPARATUS FOR STRUCTURING A NETWORK
    3.
    发明申请
    METHOD AND APPARATUS FOR STRUCTURING A NETWORK 审中-公开
    用于结构化网络的方法和装置

    公开(公告)号：US20140059089A1

    公开(公告)日：2014-02-27

    申请号：US13994735

    申请日：2011-12-16

    申请人： John Alexander Bryden

    发明人： John Alexander Bryden

    IPC分类号： G06F17/30

    CPC分类号： G06F16/21 ,  G06F16/35

    摘要： There is provided a method of structuring a network of nodes, comprising: providing link information relating to existing links between the nodes (2); using the link information to partition the network into non-predetermined groups of related nodes (3), thereby forming a group structure for the network; identifying for each group a corpus of information associated with the nodes in that group (4); generating for each group a machine-readable characterisation of that group based on the corpus of information identified for the group (5); and structuring the network of nodes through the groups and their associated characterisations (2 to 7).

    摘要翻译： 提供了一种构造节点网络的方法，包括：提供与节点（2）之间的现有链路相关的链接信息; 使用链接信息将网络划分成非预定的相关节点组（3），从而形成网络的组结构; 识别每个组中与该组中的节点相关联的信息语料库（4）; 基于为组识别的信息语料库（5），为每个组生成该组的机器可读特征; 并通过组及其相关特征构建节点网络（2到7）。

    OLIGOMERS
    4.
    发明申请
    OLIGOMERS 有权
    低分子

    公开(公告)号：US20120065244A1

    公开(公告)日：2012-03-15

    申请号：US13204326

    申请日：2011-08-05

    申请人： Linda Popplewell ,  Ian Graham ,  John George Dickson

    发明人： Linda Popplewell ,  Ian Graham ,  John George Dickson

    IPC分类号： A61K31/7088 ,  C12N15/63 ,  C07H21/04

    CPC分类号： C12N15/113 ,  A61K31/7088 ,  C12N15/115 ,  C12N2310/11 ,  C12N2310/321 ,  C12N2310/3233 ,  C12N2310/351 ,  C12N2310/3513 ,  C12N2320/31 ,  C12N2320/35

    摘要： Molecules are provided for inducing or facilitating exon skipping in forming spliced mRNA products from pre-mRNA molecules in cells. The molecules may be provided directly as oligonucleotides or expression products of vectors that are administered to a subject. High rates of skipping can be achieved. High rates of skipping reduce the severity of a disease like Duchene Muscular Dystrophy so that the disease is more like Becker Muscular Dystrophy. This is a severe reduction in symptom severity and mortality.

    摘要翻译： 提供分子用于诱导或促进外显子跳跃以在细胞中从mRNA前分子形成剪接的mRNA产物。 分子可以直接作为寡核苷酸提供，或者被施用于受试者的载体的表达产物。 可以实现高跳脱率。 跳高率降低了像Duchene肌营养不良这样的疾病的严重程度，使得该疾病更像是Becker肌营养不良症。 这是症状严重程度和死亡率的严重降低。

    CURRENT SENSING NOISE THERMOMETER
    5.
    发明申请
    CURRENT SENSING NOISE THERMOMETER 有权

    公开(公告)号：US20230098909A1

    公开(公告)日：2023-03-30

    申请号：US18050217

    申请日：2022-10-27

    申请人： Royal Holloway and Bedford New College

    发明人： Andrew James CASEY ,  John SAUNDERS ,  Lev Vitalievich LEVITIN ,  Harriet VAN DER VLIET

    IPC分类号： G01K7/30

    摘要： A current sensing noise thermometer comprising: a sensor resistor thermally coupled to a target to be measured; a superconducting coil; superconducting thermal breaks between respective ends of the sensor resistor and respective ends of the superconducting coil; and a superconducting flux sensor; wherein the sensor resistor, superconducting coil and superconducting thermal breaks form a loop inductively coupled to the superconducting flux sensor. There may be a noise filter between the sensor resistor and the superconducting coil.

    OLIGOMERS
    6.
    发明申请
    OLIGOMERS 有权

    公开(公告)号：US20220195438A1

    公开(公告)日：2022-06-23

    申请号：US17405439

    申请日：2021-08-18

    申请人： Royal Holloway and Bedford New College

    发明人： John George Dickson ,  Jagjeet Kaur Kang

    IPC分类号： C12N15/113 ,  A61K47/54 ,  C07H21/04

    摘要： Certain disclosed oligomers induce exon skipping during processing of myostatin pre-mRNA. The oligomers may be in a vector or encoded by the vector. The vector is used for inducing exon skipping during processing of myostatin pre-mRNA. A therapeutically effective amount of the oligomer may be administered to a subject patient such that exon skipping during processing of myostatin pre-mRNA is induced. The administration to a subject may be used in order to increase or maintain muscle mass, or slowing degeneration of muscle mass in the subject. The administration to a subject may ameliorate muscle wasting conditions, such as muscular dystrophy. Examples of such muscular dystrophies which may be so treated include Becker's muscular dystrophy, congenital muscular dystrophy, Duchenne muscular dystrophy, distal muscular dystrophy, Emery-Dreifuss muscular dystrophy, facioscapulohumeral muscular dystrophy (FSHD), limb-girdle muscular dystrophy, myotonic muscular dystrophy, and oculopharyngeal muscular dystrophy.

    Treatment of Muscular Dystrophies
    7.
    发明申请
    Treatment of Muscular Dystrophies 有权

    公开(公告)号：US20210130426A1

    公开(公告)日：2021-05-06

    申请号：US16770358

    申请日：2018-12-05

    申请人： Royal Holloway And Bedford New College

    发明人： George Dickson ,  Linda Popplewell

    IPC分类号： C07K14/47 ,  C12N15/86

    摘要： There is described a nucleic acid molecule comprising a nucleotide sequence encoding a functional dystrophin protein. Also described is a vector, a host cell and a pharmaceutical composition comprising the nucleic acid molecule; use of the nucleic acid molecule in therapy, such as in the treatment of a muscular dystrophy; and a method of treating muscular dystrophy, the method comprising administering a therapeutically effective amount of the nucleic acid molecule to a patient suffering from a muscular dystrophy.

    Oligomers
    9.
    发明申请
    Oligomers 审中-公开

    公开(公告)号：US20130085139A1

    公开(公告)日：2013-04-04

    申请号：US13644363

    申请日：2012-10-04

    申请人： Royal Holloway and Bedford New College

    发明人： John George Dickson ,  Jagjeet Kaur Kang

    IPC分类号： A61K31/5377 ,  C12N15/85 ,  A61K31/713 ,  A61P21/00 ,  C07H21/04 ,  C07D473/34

    摘要： Certain disclosed oligomers induce exon skipping during processing of myostatin pre-mRNA. The oligomers may be in a vector or encoded by the vector. The vector is used for inducing exon skipping during processing of myostatin pre-mRNA. A therapeutically effective amount of the oligomer may be administered to a subject patient such that exon skipping during processing of myostatin pre-mRNA is induced. The administration to a subject may be used in order to increase or maintain muscle mass, or slowing degeneration of muscle mass in the subject. The administration to a subject may ameliorate muscle wasting conditions, such as muscular dystrophy. Examples of such muscular dystrophies which may be so treated include Becker's muscular dystrophy, congenital muscular dystrophy, Duchenne muscular dystrophy, distal muscular dystrophy, Emery-Dreifuss muscular dystrophy, facioscapulohumeral muscular dystrophy (FSHD), limb-girdle muscular dystrophy, myotonic muscular dystrophy, and oculopharyngeal muscular dystrophy